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Background: Mutations in the DNA damage response (DDR) factors, breast cancer 1 (BRCA1) and BRCA2, sensitize
tumor cells to poly(ADP-ribose) polymerase (PARP) inhibitors. The ataxia telangiectasia mutated (ATM) kinase is a
key DDR protein whose heterozygous germline mutation is a moderate–risk factor for developing breast cancer. In
this study, we examined whether ATM inactivation in breast cancer cell lines confers sensitivity to PARP inhibitors.
Methods: Wild-type BRCA1/2 breast cancer cells (i.e., MCF-7 and ZR-75-1 lines) were genetically manipulated to
downregulate ATM expression then assayed for cytostaticity/cytotoxicity upon treatment with PARP inhibitors,
olaparib and iniparib.
Results: When ATM-depleted cells and their relative controls were treated with olaparib (a competitive PARP-1/2
inhibitor) and iniparib (a molecule originally described as a covalent PARP-1 inhibitor) a different response to the
two compounds was observed. ATM-depletion sensitized both MCF-7 and ZR-75-1 cells to olaparib-treatment, as
assessed by short and long survival assays and cell cycle profiles. In contrast, iniparib induced only a mild,
ATM-dependent cytostatic effect in MCF-7 cells whereas ZR-75-1 cells were sensitive to this drug, independently
of ATM inactivation. These latest results might be explained by recent observations indicating that iniparib acts
with mechanisms other than PARP inhibition.
Conclusions: These data indicate that ATM-depletion can sensitize breast cancer cells to PARP inhibition, suggesting a
potential in the treatment of breast cancers low in ATM protein expression/activity, such as those arising in mutant
ATM heterozygous carriers.
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In the past few years, much effort has been made towards
identifying chemotherapeutic compounds targeting the
core components of DDR and repair pathways, which are
frequently altered in tumor cells. The goal for these new
anti cancer strategies would be to take advantage of the
cancer cell defects in repairing their own DNA and use
it as an Achille’s heel to enhance therapeutic indices,
with limited normal tissue toxicity. Among these new
compounds, PARP inhibitors have been shown to be
highly lethal to tumor cells with deficiencies in DDR
factors such as BRCA1 or BRCA2 [1,2]. The mechanism* Correspondence: soddu@ifo.it
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distribution, and reproduction in any mediumunderlining this approach is based on the concept of syn-
thetic lethality first described in the fruit fly Drosophila
[3,4] and subsequently translated into an efficient method
to design novel anticancer drugs [5,6]. Synthetic lethality
centers on targeting two separate molecular pathways that
are nonlethal when disrupted individually, but are lethal
when inhibited simultaneously [7].
In the case of PARP inhibitors and BRCA1/2 mutations,
the two molecular pathways whose concomitant inactiva-
tion promotes a synthetic lethal relationship are the basic
excision repair (BER), responsible for the repair of single-
strand DNA breaks (SSBs), and the homologous recom-
bination (HR), that repairs double strand DNA breaks
(DSBs). In particular, BER inactivation by PARP inhibitors
induces SSBs that during DNA replication cause lethal
breaks in both DNA strands. In normal cells, the latterd Central Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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is defective, such as in the presence of BRCA1/2 mutations,
DSBs are not repaired and their accumulation causes cell
death [1,2]. These original observations have led to PARP
inhibitors entering subsequent phase II clinical trials in
breast and ovarian cancer patients, with or without BRCA
mutations [8-10]. At present, the data from clinical studies
are not as favorable as promised by the preliminary results
[11,12]. Though there might be various causes explaining
the clinical performance of the different PARP inhibitors,
one of the challenging issues remains on how to identify
those patients most receptive to these treatments [13].
Deficiency in several DDR factors other than BRCA1/2
belonging, directly or indirectly, to the HR repair pathway
have been shown to sensitize tumor cells to PARP inhib-
ition [14] and synthetic lethal-siRNA screens have identified
ATM among the genes whose depletion might mediate the
sensitivity to PARP inhibitors [15]. Recently, ATM-deficient
mantle cell lymphoma, chronic lymphocytic leukemia,
and T-prolymphocytic leukemia have been shown to be
more sensitive to PARP inhibitors than ATM-proficient cells
[16,17] suggesting that ATM mutation/inactivation might
predict responses of individual tumors to PARP inhibitors.
ATM is one of the key DNA damage sensors that have a
critical role in contributing to DDR by regulating cell cycle
checkpoints, DNA repair machinery, replication forks, and
telomeres [18,19]. Homozygous mutations of ATM are
responsible for ataxia-telangiectasia (A-T), a rare autosomal
recessive disease mainly characterized by progressive
degeneration in the cerebellum, immunodeficiency, radio-
sensitivity, and cancer predisposition [20,21]. Although
A-T heterozygotes are usually asymptomatic and, overall
considered healthy carriers, a link between single copy
ATM mutations and a two to five fold risk of breast cancer
has been established [22]. Recently, we have developed a
straightforward, rapid, and inexpensive test to unambigu-
ously diagnose A-T heterozygotes that would allow an easy
recognition of breast cancer patients carrying monoallelic
ATM germline mutations [23].
In the current studies, we assessed whether ATM
depletion by RNA interference sensitize cells from breast
cancer lines to PARP inhibitors. As ATM mutations and
loss of ATM expression can be found in hereditary and
sporadic breast cancers and A-T heterozygotes can be
diagnosed [23], we hypothesized that such data might
be useful in extending the molecular predictors required
for selecting patients responsive to PARP inhibition.
Materials and methods
Cell culture and reagents
Human breast cancer cell lines, MCF-7 and ZR-75-1, and
their transfected-derivatives were maintained in DMEM-
Glutamax and RPMI-Glutamax, respectively, supplemented
with 10% fetal bovine serum, 100 U/ml penicillin, and100 U/ml streptomycin (all from Invitrogen). All cell lines
were maintained in a 5% CO2 atmosphere at 37°C. Cells
were passaged once every 3–5 days (~90% confluence)
and all experiments were performed within the first 10
passages from transfection. For drug treatment, doxorubi-
cin (Sigma) and PARP inhibitors, olaparib and iniparib
(Selleckchem), were prepared as stock solution in water or
DMSO, respectively, aliquot and stored at −80°C until use.
Stable knockdown of ATM in cells of breast cancer lines
Stable interference was obtained by retroviral-mediated
expression of short-hairpin RNA (shRNA) using pRETRO-
Super vector. Retroviruses were produced in HEK 293 T
cells by cotransfecting pRETRO-Super together with
plasmids encoding for gag-pol and VSV-G proteins. Viral
supernatant was collected 48 hrs post-transfection, filtered
through a 0.45 μm pore size filter and added to the cells
in the presence of 2 μg/ml polybrene. After 48 hrs from
infection, stable polyclonal populations of control and
ATM-depleted cells were obtained by selection for two
weeks with 2 μg/ml puromycin (Sigma).
The shATM construct (#1 position 912) in pRETRO-
Super, generously provided by Y. Lerenthal and Y. Shiloh,
has the following sequence: 5′-GAC TTT GGC TGT CAA
CTT TCG-3′ [24]. Control shRNA, siR5, has the following
sequence: 5′-GGA TAT CCC TCT AGA TTA-3′. Neither
the ATM-targeting shRNA nor the control sequences have
any homology with other human gene as tested by BLAST
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Western blotting
Total cell extracts were prepared in lysis buffer [50 mM
Tris–HCl pH 8, 300 mM NaCl, 1 mM EDTA, 0.5% sodium
deoxycholate, 0.1% SDS, 1% Nonidet-P40, 1 mM EDTA]
supplemented with protease-inhibitor mix (Roche), re-
solved on precast NuPAGE 4-12% gels (Invitrogen), and
transferred onto nitrocellulose membranes (Bio-Rad). The
following antibodies were employed for immunedetection:
rabbit anti-ATM (Santa Cruz), mouse anti-α-tubulin (Im-
munological Sciences), HRP-conjugated goat anti-mouse
and anti-rabbit (Cappel). Immunoreactivity was determined
using the ECL-chemiluminescence reaction (Amersham
Corp) following the manufacturer’s instructions.
Ionizing radiation (IR)
When indicated, cells were irradiated using a 137Cs source
(IBL-437-C irradiator, CIS bio International) at a dose rate
of 6.8 Gy/min.
Citotoxicity and BrdU assays
Cells (5 × 104/ml) were seeded in 96-well plates in growth
medium and incubated 24 hrs at 37°C in 5% CO2 atmos-
phere. Drugs were added at the indicated concentrations
and for the indicated times before incubation with reagents
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Science), following the manufacturer’s instructions. The
absorbance at 450 nm (XTT and WST-1) or at 370 nm
(BrdU) were measured by the microplate reader Infinite
F200 (Tecan). Each experiment was performed in triplicate.
The survival fraction for a given dose was calculated as
the plating efficiencies for that dose divided by the plating
efficiencies of solvent-treated cells.
Cell cycle profiles
Treated and untreated cells (5 × 105) were washed in PBS
1X and resuspended in 300 μl hypotonic fluorochrome
solution [50 μg/ml propidium iodide, 0.1% sodium citrate,
0.1% Triton-X-100 (all from Sigma)] for 30 min at room
temperature. DNA content was measured by a FACScan
flow cytometer (Becton Dickinson).
Colony forming assays
Cells were treated with drugs at the indicated doses for
24 hrs, then plated at low density in 60 mm Petri dishes
and grown for twelve days in the absence of drugs.
Surviving colonies were fixed and stained with Cristal
Violet (0.5% in methanol) (Sigma), air-dried, and counted.
Statistics
The Wilcoxon test for paired samples has been used for
repeated measurements. A p-value less than 0.10 (*) and
less than 0.05 (**) were considered statistical significant.
Results and discussion
Effects of ATM-depletion in breast cancer MCF-7 cell line
To assess the influence of ATM in breast cancer suscepti-
bility to PARP inhibitors, we genetically repressed ATM
expression by RNA interference in MCF-7 cells. We chose
the MCF-7 breast cancer cell line because it is ER positive,
HER2 negative, and wild-type for the BRCA1, BRCA2, and
TP53 genes [25], features we observed in breast tumors
arising in our A-T heterozygotes [23]. Stable interference
of ATM was obtained by MCF-7 transfection with
shATM-carrying vectors (MCF7-ATMi) and its siR5
negative control (MCF7-ctr) (see Materials and methods).
Stable-transfected cells were selected in the presence of
puromycin for ten days and maintained as polyclonal
populations. As shown in Figure 1A, a strong repression
of ATM expression was obtained in the MCF7-ATMi
cells compared to the MCF7-ctr ones. To verify whether
ATM-depletion has a functional impact on MCF-7 cells,
we assessed the sensitivity of ATM-depleted and control
cells to IR and doxorubicin treatment, that are known to
induce different outcomes in ATM proficient and defective
cells. In particular, radiosensitivity is a defining feature
of ATM-defective cells [26] whereas, in a wild-type p53
context, doxorubicin-resistance was shown to characterize
ATM-deficient cells in vitro [27] and in breast cancerpatients [28]. As shown in Figure 1B and 1C, MCF7-ATMi
cells were more sensitive to IR and more resistant to doxo-
rubicin than MCF7-ctr cells. The contribution of ATM in
the latter result was confirmed in MCF-7 parental cells by
KU 55933-induced ATM inactivation (Figure 1D). These
results were further confirmed by evaluating the cell cycle
profiles (Figure 1E). After 24 hrs from irradiation, both
MCF7-ctr and MCF7-ATMi cells show the expected
enrichment into the G2/M phase. After 48 hrs from
irradiation, MCF7-ctr cells repair the damage and re-enter
into the cell cycle; in contrast, MCF7-ATMi cells, which
are known to have defects in sensing and repairing DNA
double strand breaks [26], show a delay in re-entering into
the cell cycle. In contrast, as expected from the data
reported by Jiang and co-workers [27], the ATMi cells
were more resistant to doxorubicin and a lower propor-
tion of cells underwent cell death.
Altogether, these results show that MCF-7 transduction
with shATM-carrying vectors interferes with ATM expres-
sion and elicits some aspects of a phenotype compatible
with ATM-deficient cells.
ATM-depletion sensitizes MCF-7 cells to olaparib
To evaluate whether ATM-depletion modifies MCF-7
response to PARP inhibitors, we first used olaparib
(AZD2281, Ku-0059436), an orally bioavailable compound
whose effectiveness in BRCA1/2 mutated breast and ovar-
ian cancers was studied in phase II clinical trials and, for
ovarian cancers is under further evaluation in phase III
clinical studies [12]. MCF7-ATMi and MCF7-ctr cells
were incubated with increasing concentrations of olaparib
or its solvent (DMSO) for 72 hrs and their viability
assessed by XTT or WST-1, with comparable results. As
shown in Figure 2A, ATM-depleted cells were mildly but
significantly more sensitive than MCF7-ctr cells to olaparib.
However, MCF7-ctr cells, as well as the parental MCF-7
cells (data not shown) were not completely resistant to
olaparib and their viability declined with time (Figure 2B)
and at the highest doses we employed (Figure 2A, 10 μM
dose).
To further characterize the effect induced by olaparib,
MCF7-ATMi and MCF7-ctr cells were treated for 48 hrs
with 2.5 and 5 μM olaparib and their DNA content
assessed by propidium iodide staining and FACS analysis.
Consistently with the viability assays described above, cell
death, measured by the appearance of hypodiploid cells,
was detected only in the olaparib-treated MCF7-ATMi
cells (Figure 2C). However, both ATM-depleted and control
MCF-7 cells arrested in the G2/M phase of the cell cycle, in
a dose-dependent manner, as previously described [2]. The
similarity in the cell cycle behavior between MCF7-ATMi
and MCF7-ctr cells after olaparib treatment was confirmed
by BrdU assay that showed a comparable reduction in the
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Figure 1 MCF-7 transduction with shATM-carrying vectors elicits a phenotype compatible with ATM defective cells. (A) MCF-7 cells
were transfected with shATM-carrying vector (MCF7-ATMi) and its siR5 negative control (MCF7-ctr). ATM protein levels in MCF-7-ATMi and
MCF-7-ctr cells were analyzed by Western blot. α-tubulin was used as an internal control. B-D Cell viability of MCF7-ATMi and MCF7-ctr cells
upon treatment with IR (B) and doxorubicin (C). (D) MCF7-ctr cells were pre-treated with ATM inhibitor KU 55933 or its solvent before
addition of doxorubicin as in (C). Data are represented as mean ± standard deviation (SD). (E) Flow cytometry analysis of cell-cycle distribution of
MCF7-ATMi and MCF7-ctr cells upon treatment with IR and doxorubicin at indicated times. Asterisks indicate statistical significant difference
(*P < 0.1; **P < 0.05).















































subG1: 16 % 
G2/M: 51 % 
subG1: 3.2 % 
G2/M: 60 % 
Olap 2.5µM 
subG1: 14 % 
G2/M: 69 % 
subG1: 3.8 % 
G2/M: 72 % 
Olap 5µM 
subG1: 8.7 % 
G2/M: 30 % 
DMSO 
subG1: 5.2 % 


















































Figure 2 (See legend on next page.)
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Figure 3 MCF7-ATMi cells are more sensitive than MCF7-ctr cells to iniparib. (A) Quantitative analyses of colony formation. The numbers of
DMSO-resistant colonies in MCF7-ATMi and MCF7-ctr cells were set to 100, while iniparib treated cel1s were presented as mean ± SD. (B) Flow
cytometry analysis of cell-cycle distribution of MCF7-ATMi and MCF7-ctr cells treated with the indicated concentrations of iniparib for 48 hrs.
(C) DNA synthesis was measured by BrdU incorporation assay 48 hrs after iniparib treatment. Data are represented as mean ± SD. Asterisks
indicate statistical significant difference (*P < 0.1; **P < 0.05).
(See figure on previous page.)
Figure 2 MCF7-ATMi cells are more sensitive than MCF7-ctr cells to olaparib. A-B MCF7-ATMi and MCF7-ctr cells were exposed to increased
concentrations of olaparib for 72 hrs (A) or were treated with olaparib (5 μM) for up to 96 hrs (B). Data are represented as mean ± SD. (C) Flow
cytometry analysis of cell-cycle distribution of MCF7-ATMi and MCF7-ctr cells treated with the indicated concentrations with olaparib for 48 hrs.
(D) DNA synthesis was measured by BrdU incorporation assay 48 hrs after olaparib treatment. (E) Quantitative analyses of colony formation.
The numbers of DMSO-resistant colonies in MCF7-ATMi and MCF7-ctr cells were set to 100, while olaparib treated cel1s were presented as
mean ± SD. Asterisks indicate statistical significant difference (*P < 0.1).
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Figure 4 (See legend on next page.)
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Figure 4 ZR-ATMi cells are more sensitive than ZR-ctr cells to olaparib but not to iniparib. (A) ZR-75-1 cells were transfected with
shATM-carrying vector (ZR-ATMi) and its siR5 negative control (ZR-ctr). ATM protein levels in ZR-ATMi and ZR-ctr cells were analyzed by Western
blot. α-tubulin was used as an internal control. B-C ZR-ATMi and ZR-ctr cells were exposed to increased concentrations of olaparib (B) or iniparib
for 72 hrs (C). Data are represented as mean ± SD. (D) Flow cytometry analysis of cell-cycle distribution of ZR-ATMi and ZR-ctr cells treated with
the indicated concentrations with olaparib or iniparib for 72 hrs. E-F Quantitative analyses of colony formation. The numbers of DMSO-resistant
colonies in ZR-ATMi and ZR-ctr cells were set to 100, while olaparib (E) or iniparib (F) treated cel1s were presented as mean ± SD. Asterisks
indicate statistical significant difference (*P < 0.1; **P < 0.05).
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depletion, but these cells are partially responsive to this
compound, as also recently reported by others [29].
Next, we verified the long-term effect of olaparib by
performing colony formation assays. MCF7-ATMi and
MCF7-ctr cells were treated for 24 hrs with 0.5 and
1 μM olaparib, then plated at low density and grown
for twelve days in the absence of drug. As shown in
Figure 2E, a significant reduction in the colony forming
capacity was observed in the ATM-depleted cells compared
to the controls. Consistent with the results described above,
a mild reduction in colony formation was also observed in
the olaparib-treated MCF7-ctr cells compared with their
DMSO-treated controls (Figure 2E, blue columns).
Overall, these data indicate that ATM-depletion increases
sensitivity to olaparib in breast cancer MCF-7 cells;
however, factors other than ATM might contribute to the
response of this cell line to this PARP-inhibitor.
ATM-depletion sensitizes MCF-7 cells to iniparib
Next, we asked whether ATM-depletion can sensitize
MCF-7 cells to iniparib (BSI-201, SAR240550), a com-
pound originally described as an irreversible inhibitor of
PARP-1 [30], but recently shown to act as a nonselective
modifier of cysteine-containing proteins [31,32]. MCF7-
ATMi and MCF7-ctr cells were treated with iniparib or
its solvent, DMSO, and analyzed for colony formation
capacity, DNA content by FACS analysis, and BrdU assay.
As shown in Figure 3A, ATM-depletion reduced the ability
of MCF-7 cells to produce colonies after iniparib-treatment
while no effect was observed in MCF7-ctr cells. At variance
with olaparib-treatment, DNA content analysis did not
reveal any significant difference between MCF7-ATMi and
MCF7-ctr cells in the appearance of hypodiploid, death
cells, whereas only the MCF7-ATMi population experi-
enced an accumulation of cells in the G2/M phase of the
cell cycle (Figure 3B). This effect on the cell cycle was
confirmed by BrdU assays (Figure 3C). Together, these
results suggest that ATM-depletion can also influence
MCF-7 cell response to iniparib.
ATM-depletion sensitizes ZR-75-1 breast cancer cells
to olaparib but not to iniparib
To further assess the impact of ATM-depletion in breast
cancer cell response to olaparib and iniparib, we selectedthe ZR-75-1 line, whose cells, like the MCF-7 ones, are ER
positive, HER2 negative, and wild-type for BRCA1/2 and
TP53 genes [25]. Stable interference of ATM in ZR-75-1
cells was obtained as described for MCF-7 cells. Polyclonal
populations, ZR-ATMi and ZR-ctr, were obtained by puro-
mycin selection and ATM-depletion confirmed by Western
blot analysis (Figure 4A). Next, dose–response viability
assays were performed on ZR-ATMi and ZR-ctr cells upon
incubation with olaparib, iniparib, or their solvent, DMSO.
As shown in Figures 4B, ZR-ctr cells were strongly resistant
to olaparib whereas their ATM-depleted counterpart be-
came considerably sensitive and showed a partial accumu-
lation in the G2/M phase of the cell cycle (Figure 4D).
These results, confirmed by colony formation assays
(Figure 4E), sustain the observations made with MCF-7
cells and support a synthetic lethal relationship between
ATM-depletion and olaparib-treatment in ER positive,
wild-type BRCA 1/2 breast cancer cells.
In contrast with the sensitivity induced by ATM-
depletion in MCF-7 cells, when treated with iniparib, both
ZR-ATMi and ZR-ctr cells showed a substantial loss of
viability that was independent of ATM, as indicated by the
similarity of their survival curves (Figure 4C) and cell cycle
distribution (Figure 4D). These results were confirmed by
the complete inhibition of colony formation induced by
iniparib in ZR-75-1 cells, independent of their ATM status
(Figure 4F). In addition, the different response between
MCF-7 and ZR-75-1 cells to this drug suggests that ER
expression and the wild-type status of BRCA1/2 and
TP53 are not involved in the sensitivity to iniparib.
These results might be explained by the recent observations
indicating that the primary mechanism of action for ini-
parib is a nonselective modification of cysteine-containing
proteins, rather then inhibition of PARP activity [32].
Conclusions
In a few hematological malignancies, ATM-deficiency was
shown to confer sensitivity to PARP inhibitors, indicating
that ATM might be included in the DDR factors whose
mutation or loss of expression confer sensitivity to this class
of drugs. Based on these observations, we asked whether
ATM deficiency plays a similar role in breast cancer, the
solid tumor linked to ATM germline mutations. For this
study, we employed two breast-cancer cell lines selected
among those showing the molecular feature we recently
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In addition, we selected two compounds, olaparib and ini-
parib, originally described as PARP inhibitors. We show
that ATM-depletion confers sensitivity to olaparib in both
cell lines and a mild sensitivity to iniparib in the MCF-7
cells indicating that ATM mutation/inactivation might be
consider in the selection of breast cancers responsive to
PARP inhibition.
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